The Drug-Induced Respiratory Disease Website and App

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.i Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.ap Pulmonary infiltrates

XLV. Pleural and/or pericardial involvement

XLV.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

LI. Cardiovascular involvement / toxicity

LI.c Pericardial effusion (w/wo tamponade)

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.a BAL: An excess proportion of lymphocytes

LVIII. Pathology

LVIII.a Path: NSIP-cellular pattern (see also Ia, Ib)

LXII. Rechallenge data

LXII.e Rechallenge may not necessarily lead to relapse of AE/ILD

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.i Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.l Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.t A mass or masses

I. Interstitial/parenchymal lung disease

I.v Relapsing or migrating pneumonitis/pneumonia (see also Id)

I. Interstitial/parenchymal lung disease

I.x Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

I. Interstitial/parenchymal lung disease

I.aa An area or areas of consolidation

I. Interstitial/parenchymal lung disease

I.ab Delayed ILD, -pneumonitis, -fibrosis

I. Interstitial/parenchymal lung disease

I.ap Pulmonary infiltrates

I. Interstitial/parenchymal lung disease

I.au Amiodarone pulmonary toxicity - Amiodarone lung

I. Interstitial/parenchymal lung disease

I.ay Chronic pneumonitis

I. Interstitial/parenchymal lung disease

I.az Unilateral interstitial lung disease

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.m Postoperative ARDS

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.a Alveolar hemorrhage (AH), diffuse AH (DAH)

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.c Hemoptysis

XLIII. Airway involvement

XLIII.a Bronchospasm - Wheezing - Asthma

XLIII. Airway involvement

XLIII.k Airway pigmentation (black, bluish, petechial)

XLIII. Airway involvement

XLIII.ab Cough (lone)

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.a Angioedema (may cause UAO, asphyxia and death)

XLV. Pleural and/or pericardial involvement

XLV.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XLV. Pleural and/or pericardial involvement

XLV.c Pleural thickening - Fibrothorax

XLV. Pleural and/or pericardial involvement

XLV.d Pleural/pericardial effusion, ANA positive (DI lupus)

XLV. Pleural and/or pericardial involvement

XLV.u The apical cap

XLVI. Pulmonary vasculopathy

XLVI.a Pulmonary embolism - Venous thrombosis/thromboembolism

XLVI. Pulmonary vasculopathy

XLVI.i Acute pulmonary hypertension

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.d Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.ai Acute respiratory failure (hypoxemia, acidosis) from myxedema (-coma)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.d Lupus - Lupus syndrome (see also Vd)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.s Systemic inflammatory response

L. Miscellaneous

L.c Pleuritic chest pain

L. Miscellaneous

L.g Bluish, pseudocyanotic skin discoloration

LI. Cardiovascular involvement / toxicity

LI.a Left or biventricular dysfunction/failure

LI. Cardiovascular involvement / toxicity

LI.c Pericardial effusion (w/wo tamponade)

LI. Cardiovascular involvement / toxicity

LI.f Takotsubo (stress) cardiomyopathy

LI. Cardiovascular involvement / toxicity

LI.n Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

LI. Cardiovascular involvement / toxicity

LI.o Cardiovascular collapse - Cardiogenic shock - Hypotension

LI. Cardiovascular involvement / toxicity

LI.q QTc prolongation

LI. Cardiovascular involvement / toxicity

LI.v Torsades de pointe

LI. Cardiovascular involvement / toxicity

LI.ah Coronary vasospasm - Vasospastic angina

LI. Cardiovascular involvement / toxicity

LI.aw Heart failure (thyrotoxicosis-, thyroid storm-mediated)

LIV. Pulmonary physiology - PFTs

LIV.g Platypnea-orthodeoxia

LV. Imaging

LV.b Imaging: Ground-glass opacities (GGO) / shadowing

LV. Imaging

LV.i Imaging: An area or areas of involvement with a recognizable anatomic distribution

LV. Imaging

LV.j Imaging: Wandering (migratory) pulmonary opacities

LV. Imaging

LV.n Imaging: Intralobular septal thickening - Crazy paving

LV. Imaging

LV.s Imaging: An area or areas of involvement with high attenuation numbers or metallic density

LV. Imaging

LV.w Imaging: Lung nodule or nodules

LV. Imaging

LV.x Imaging: Waxing and waning nodules

LV. Imaging

LV.ab Imaging: Nodules, mass or masses with a central area of low attenuation (see also under XVIaa)

LV. Imaging

LV.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

LV. Imaging

LV.ba Imaging: Asymmetrical, predominantly unilateral involvement

LV. Imaging

LV.bb Imaging: Solitary pulmonary nodule

LV. Imaging

LV.bn Imaging: Atelectasis (a combination of increased density and volume loss. Typically lobar)

LV. Imaging

LV.bt Imaging: A pattern consistent with pleuroparenchymal fibroelastosis

LV. Imaging

LV.bv Imaging: A subsolid lung nodule or nodules

LV. Imaging

LV.cb Imaging: Disseminated patchy pulmonary opacities

LVI. Distinctive patterns - 'Eye-catchers'

LVI.b Eye catcher: Electron-dense area or areas of consolidation on unenhanced chest CT

LVI. Distinctive patterns - 'Eye-catchers'

LVI.j Eye-catcher: Avid lung uptake on 18F-PET-CT

LVI. Distinctive patterns - 'Eye-catchers'

LVI.k Eye-catcher: An electron-dense liver on unenhanced CT

LVI. Distinctive patterns - 'Eye-catchers'

LVI.p Eye-catcher: An electron-dense ('white') thyroid

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.a BAL: An excess proportion of lymphocytes

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.b BAL: An excess proportion of neutrophils

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.c BAL: An excess proportion of eosinophils

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.e BAL: Stainable iron in macrophages

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.f BAL: Foamy macrophages

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.m BAL: A normal cell differential

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.p BAL: Lamellar bodies in AM on EM

LVIII. Pathology

LVIII.a Path: NSIP-cellular pattern (see also Ia, Ib)

LVIII. Pathology

LVIII.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

LVIII. Pathology

LVIII.c Path: Acute eosinophilic pneumonia pattern (see also under XVIb)

LVIII. Pathology

LVIII.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

LVIII. Pathology

LVIII.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

LVIII. Pathology

LVIII.k Path: Desquamative interstitial pneumonia (DIP-pattern)

LVIII. Pathology

LVIII.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

LVIII. Pathology

LVIII.q Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)

LVIII. Pathology

LVIII.r Path: Alveolar hemorrhage (see also IIIa)

LVIII. Pathology

LVIII.v Path: NSIP-fibrotic pattern

LVIII. Pathology

LVIII.w Path: Pulmonary fibrosis (UIP-pattern)

LVIII. Pathology

LVIII.aa Path: Endogenous lipoid pneumonia (phospholipidosis)

LVIII. Pathology

LVIII.ae Path: Foamy inclusions in alveolar macrophages and/or in other lung cells

LVIII. Pathology

LVIII.ag Path: Histiocytic proliferation

LVIII. Pathology

LVIII.aj Path: Lymphoid hyperplasia (including nodular- or a lymphocytic interstitial pneumonia pattern)

LVIII. Pathology

LVIII.ak Path: Smudged geographic necrosis

LVIII. Pathology

LVIII.bm Path: Pleuritis, pleural fibrosis

LIX. Infections & related conditions

LIX.e Pneumocystis jiroveci pneumonia

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.i Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.l Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.n ILD with a granulomatous component

I. Interstitial/parenchymal lung disease

I.o Pulmonary alveolar proteinosis (PAP)

I. Interstitial/parenchymal lung disease

I.w Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.x Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

I. Interstitial/parenchymal lung disease

I.y Pleuroparenchymal fibroelastosis (PPFE)

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

I. Interstitial/parenchymal lung disease

I.ab Delayed ILD, -pneumonitis, -fibrosis

I. Interstitial/parenchymal lung disease

I.ae Radiation recall pneumonitis

I. Interstitial/parenchymal lung disease

I.av The chemotherapy lung

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.a Pulmonary edema, noncardiogenic (NCPE)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.b Pulmonary edema, cardiogenic

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.f ARDS and the hemolytic-uremic syndrome (HUS)

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.a Alveolar hemorrhage (AH), diffuse AH (DAH)

XLIII. Airway involvement

XLIII.a Bronchospasm - Wheezing - Asthma

XLIII. Airway involvement

XLIII.j Bronchiectasis

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.a Angioedema (may cause UAO, asphyxia and death)

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.g Vocal cord paresis/paralysis

XLV. Pleural and/or pericardial involvement

XLV.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XLV. Pleural and/or pericardial involvement

XLV.f Pneumothorax

XLV. Pleural and/or pericardial involvement

XLV.ac Pneumothorax, bilateral

XLVI. Pulmonary vasculopathy

XLVI.b Pulmonary arterial hypertension

XLVI. Pulmonary vasculopathy

XLVI.c Pulmonary veno-occlusive disease

XLVI. Pulmonary vasculopathy

XLVI.f Hemolytic and uremic syndrome (HUS). See also under Xaf

XLVII. Mediastinal involvement

XLVII.a Lymphadenopathy (intrathoracic)

XLVII. Mediastinal involvement

XLVII.h Pneumomediastinum

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.f Hiccup

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.j Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.o Pneumorachis

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.c Capillary leak syndrome (CLS)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.d Lupus - Lupus syndrome (see also Vd)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.m Sarcoid-like granulomatosis (endo-/extrathoracic)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.p Tumor lysis syndrome (TLS)

L. Miscellaneous

L.b Chest pain (acute or subacute), lone or prominent

L. Miscellaneous

L.l Neutropenia, agranulocytosis (w/wo infection/sepsis)

L. Miscellaneous

L.t Cavitation/necrosis of lung tumor or metastases

LI. Cardiovascular involvement / toxicity

LI.a Left or biventricular dysfunction/failure

LI. Cardiovascular involvement / toxicity

LI.b Valvular heart disease and/or dysfunction

LI. Cardiovascular involvement / toxicity

LI.c Pericardial effusion (w/wo tamponade)

LI. Cardiovascular involvement / toxicity

LI.f Takotsubo (stress) cardiomyopathy

LI. Cardiovascular involvement / toxicity

LI.g Cardiomyopathy (acute, subacute, chronic)

LI. Cardiovascular involvement / toxicity

LI.h Coronary artery disease (acute) - Myocardial ischemia/infarction

LI. Cardiovascular involvement / toxicity

LI.m Atrial fibrillation

LI. Cardiovascular involvement / toxicity

LI.n Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

LI. Cardiovascular involvement / toxicity

LI.t Heart block (bundle branch- or AV-)

LI. Cardiovascular involvement / toxicity

LI.ak Cardiotoxicity

LV. Imaging

LV.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

LV. Imaging

LV.ad Imaging: Lung cysts or bullae (see also XVI ah/bf)

LV. Imaging

LV.bh Imaging: Tumoral cavitation

LV. Imaging

LV.bp Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan

LV. Imaging

LV.by Imaging: Air or an air crescent around lung tumor or metastase(s)

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.g BAL: Atypical epithelial cells (at times poetically named

LVIII. Pathology

LVIII.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

LVIII. Pathology

LVIII.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

LVIII. Pathology

LVIII.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

LVIII. Pathology

LVIII.q Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)

LVIII. Pathology

LVIII.x Path: Pulmonary fibrosis (not otherwise specified or unclassifiable)

LVIII. Pathology

LVIII.ba Path: Thrombosis in pulmonary arterioles/venules

LVIII. Pathology

LVIII.bd Path: Pulmonary veno-occlusive disease (PVOD)

LVIII. Pathology

LVIII.bx Path: Granulomatous lymphadenopathy

LIX. Infections & related conditions

LIX.b Opportunistic pulmonary/systemic infections

LIX. Infections & related conditions

LIX.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

LIX. Infections & related conditions

LIX.e Pneumocystis jiroveci pneumonia

LIX. Infections & related conditions

LIX.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

LIX. Infections & related conditions

LIX.j Mucormycosis (pulmonary, tracheobronchial or systemic)

LIX. Infections & related conditions

LIX.r Fungal infection (pulmonary/extrapulmonary)

LIX. Infections & related conditions

LIX.ae Reactivation of a prior pulmonary infection (TB, melioidosis)

LX. Neoplastic conditions

LX.a Lung cancer

LX. Neoplastic conditions

LX.b Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)

LX. Neoplastic conditions

LX.d Malignant mesothelioma (pleural, pericardial)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.i Subclinical pulmonary infiltrates/ILD

XLIII. Airway involvement

XLIII.x Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)

XLIII. Airway involvement

XLIII.ag Obstructive airway dysfunction (see also IVc, XVx)

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.a BAL: An excess proportion of lymphocytes

LVIII. Pathology

LVIII.a Path: NSIP-cellular pattern (see also Ia, Ib)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.i Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.w Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

LXV. Veterinary medicine

LXV.a Veterinary: Pneumonitis - Interstitial lung disease

LXV. Veterinary medicine

LXV.d Veterinary: Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.i Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.w Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.x Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.a Pulmonary edema, noncardiogenic (NCPE)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.f ARDS and the hemolytic-uremic syndrome (HUS)

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.a Alveolar hemorrhage (AH), diffuse AH (DAH)

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.c Upper airway obstruction other than angioedema or hematoma

XLVI. Pulmonary vasculopathy

XLVI.b Pulmonary arterial hypertension

XLVI. Pulmonary vasculopathy

XLVI.c Pulmonary veno-occlusive disease

XLVI. Pulmonary vasculopathy

XLVI.f Hemolytic and uremic syndrome (HUS). See also under Xaf

XLVI. Pulmonary vasculopathy

XLVI.u Angiomatoid pulmonary vasculopathy

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.m Sarcoid-like granulomatosis (endo-/extrathoracic)

LVIII. Pathology

LVIII.a Path: NSIP-cellular pattern (see also Ia, Ib)

LVIII. Pathology

LVIII.q Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)

LVIII. Pathology

LVIII.bd Path: Pulmonary veno-occlusive disease (PVOD)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.i Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.ae Radiation recall pneumonitis

I. Interstitial/parenchymal lung disease

I.ak Shrinking lung syndrome

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.b Pulmonary edema, cardiogenic

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.g Bleeding/hemorrhage from/around preexisting lung tumor (Localized AH)

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.j Anti-GBM-related pneumorenal syndrome and DAH (Goodpasture) or flare of

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.m Coagulopathy

XLIII. Airway involvement

XLIII.a Bronchospasm - Wheezing - Asthma

XLIII. Airway involvement

XLIII.d Exacerbation or deterioration of preexisting COPD

XLIII. Airway involvement

XLIII.t Eosinophilic airway disease (asthma, bronchitis, bronchiolitis)

XLIII. Airway involvement

XLIII.w Bronchiolitis (a clinical-imaging pattern suggestive of)

XLIII. Airway involvement

XLIII.x Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)

XLIII. Airway involvement

XLIII.af Sputum production - Bonchorrhea - ‘Bronchitis’

XLIII. Airway involvement

XLIII.ag Obstructive airway dysfunction (see also IVc, XVx)

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.g Vocal cord paresis/paralysis

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.au Rhinosinusitis

XLV. Pleural and/or pericardial involvement

XLV.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XLV. Pleural and/or pericardial involvement

XLV.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

XLVI. Pulmonary vasculopathy

XLVI.b Pulmonary arterial hypertension

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.d Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.h Dyspnea, unexplained otherwise

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.r Myasthenia gravis - Myasthenic-like syndrome

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.y A flare or relapse of preexisting myasthenia gravis

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.ab Guillain-Barré (or GB-like) syndrome (w/wo ARF)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.a DRES syndrome - DRESS-like reaction

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.d Lupus - Lupus syndrome (see also Vd)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.l Myopathy-Myositis-Polymyositis (see also under Xba)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.m Sarcoid-like granulomatosis (endo-/extrathoracic)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.o Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.p Tumor lysis syndrome (TLS)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.u Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.w Multiple organ dysfunction/failure (MODS/MOF)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.ae Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS)

XLIX. Systemic/Distant conditions, syndromes and reactions

XLIX.az Polymyalgia rheumatica

L. Miscellaneous

L.as Deterioration of graft function in SOT recipients

L. Miscellaneous

L.bi Esophageal necrosis

LI. Cardiovascular involvement / toxicity

LI.c Pericardial effusion (w/wo tamponade)

LI. Cardiovascular involvement / toxicity

LI.d Myocarditis (can be fulminant)

LI. Cardiovascular involvement / toxicity

LI.h Coronary artery disease (acute) - Myocardial ischemia/infarction

LI. Cardiovascular involvement / toxicity

LI.o Cardiovascular collapse - Cardiogenic shock - Hypotension

LI. Cardiovascular involvement / toxicity

LI.t Heart block (bundle branch- or AV-)

LI. Cardiovascular involvement / toxicity

LI.ak Cardiotoxicity

LI. Cardiovascular involvement / toxicity

LI.az Necrotizing myocarditis (w/o evidence for CAD)

LII. Esophageal involvement

LII.c Esophageal stenosis/stricture

LII. Esophageal involvement

LII.d Esophageal toxicity

LV. Imaging

LV.i Imaging: An area or areas of involvement with a recognizable anatomic distribution

LV. Imaging

LV.v Imaging: Centrilobular micronodules (can be diffuse)

LV. Imaging

LV.w Imaging: Lung nodule or nodules

LV. Imaging

LV.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

LV. Imaging

LV.ad Imaging: Lung cysts or bullae (see also XVI ah/bf)

LV. Imaging

LV.ak Imaging: A 'tree-in-bud' pattern

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.a BAL: An excess proportion of lymphocytes

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.b BAL: An excess proportion of neutrophils

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.c BAL: An excess proportion of eosinophils

LVIII. Pathology

LVIII.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

LVIII. Pathology

LVIII.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

LVIII. Pathology

LVIII.r Path: Alveolar hemorrhage (see also IIIa)

LVIII. Pathology

LVIII.al Path: Acute/subacute bronchiolitis (see also IVc, IVi)

LVIII. Pathology

LVIII.am Path: Peribronchiolar granulomas

LVIII. Pathology

LVIII.au Path: Airway inflammation

LIX. Infections & related conditions

LIX.a Respiratory tract infection incl. pneumonia

LIX. Infections & related conditions

LIX.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

LIX. Infections & related conditions

LIX.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

LIX. Infections & related conditions

LIX.ai Bordetella bronchiseptica pulmonary infection

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.i Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.p Focal/localized area of pneumonitis/fibrosis

I. Interstitial/parenchymal lung disease

I.w Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.y Pleuroparenchymal fibroelastosis (PPFE)

XLI. Pulmonary edema - Acute lung injury - ARDS

XLI.e ARDS - Acute lung injury

XLII. Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.c Hemoptysis

XLIII. Airway involvement

XLIII.j Bronchiectasis

XLIII. Airway involvement

XLIII.ai Bronchial stenosis/stricture

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.c Upper airway obstruction other than angioedema or hematoma

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.d Laryngeal disorder-Laryngeal nerve palsy (dysphonia, hoarseness)

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.g Vocal cord paresis/paralysis

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.s Tracheal/large airway necrosis, chondronecrosis, perforation

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.aa Pseudomembranous tracheitis/tracheobronchitis

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.ab Airway (e.g. tracheoesophageal) fistula

XLIV. Central-large-upper airway (incl. pharyngeal-nasal) involvement

XLIV.ac Large airway necrosis

XLV. Pleural and/or pericardial involvement

XLV.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

XLV. Pleural and/or pericardial involvement

XLV.b Eosinophilic pleural effusion

XLV. Pleural and/or pericardial involvement

XLV.c Pleural thickening - Fibrothorax

XLV. Pleural and/or pericardial involvement

XLV.f Pneumothorax

XLV. Pleural and/or pericardial involvement

XLV.h Chylothorax

XLV. Pleural and/or pericardial involvement

XLV.l Malignant pleural mesothelioma

XLV. Pleural and/or pericardial involvement

XLV.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

XLV. Pleural and/or pericardial involvement

XLV.u The apical cap

XLVI. Pulmonary vasculopathy

XLVI.c Pulmonary veno-occlusive disease

XLVI. Pulmonary vasculopathy

XLVI.r Pulmonary artery aneurysm(s)

XLVI. Pulmonary vasculopathy

XLVI.aa Pulmonary artery stenosis

XLVII. Mediastinal involvement

XLVII.d Fibrosing mediastinitis

XLVII. Mediastinal involvement

XLVII.i Mediastinitis

XLVII. Mediastinal involvement

XLVII.j Compression of mediastinal structures/organs

XLVII. Mediastinal involvement

XLVII.l Calcification of mediastinal lymph nodes

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

XLVIII. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.aj Paraspinal muscle myositis/myopathy/neuromyopathy +- the dropped head syndrome

L. Miscellaneous

L.h Aspiration, aspiration pneumonia (w/wo demonstrable pharyngeal dysmotility)

L. Miscellaneous

L.m Chest deformity: platythorax

L. Miscellaneous

L.s Rib fracture

L. Miscellaneous

L.ad Vertebral compression fracture

L. Miscellaneous

L.bc Aorto-esophageal fistula

L. Miscellaneous

L.bn Dropped-head syndrome

LI. Cardiovascular involvement / toxicity

LI.a Left or biventricular dysfunction/failure

LI. Cardiovascular involvement / toxicity

LI.b Valvular heart disease and/or dysfunction

LI. Cardiovascular involvement / toxicity

LI.g Cardiomyopathy (acute, subacute, chronic)

LI. Cardiovascular involvement / toxicity

LI.h Coronary artery disease (acute) - Myocardial ischemia/infarction

LI. Cardiovascular involvement / toxicity

LI.l Constrictive pericarditis - Pericardial thickening

LI. Cardiovascular involvement / toxicity

LI.p Coronary artery disease (subacute, chronic)

LI. Cardiovascular involvement / toxicity

LI.t Heart block (bundle branch- or AV-)

LI. Cardiovascular involvement / toxicity

LI.af Effusive-constrictive pericarditis

LI. Cardiovascular involvement / toxicity

LI.am Late left ventricular dysfunction/failure

LI. Cardiovascular involvement / toxicity

LI.ap Pericardial calcification

LI. Cardiovascular involvement / toxicity

LI.bf Coarctation of the aorta (acquired)

LI. Cardiovascular involvement / toxicity

LI.bx Aortoesophageal fistula

LII. Esophageal involvement

LII.b Esophageal pathology (erosion, ulcer, tear, rupture, fistula)

LII. Esophageal involvement

LII.c Esophageal stenosis/stricture

LII. Esophageal involvement

LII.d Esophageal toxicity

LV. Imaging

LV.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

LV. Imaging

LV.bm Imaging: Hyperlucent lung

LV. Imaging

LV.bn Imaging: Atelectasis (a combination of increased density and volume loss. Typically lobar)

LV. Imaging

LV.bp Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan

LVIII. Pathology

LVIII.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

LVIII. Pathology

LVIII.x Path: Pulmonary fibrosis (not otherwise specified or unclassifiable)

LX. Neoplastic conditions

LX.a Lung cancer

LX. Neoplastic conditions

LX.d Malignant mesothelioma (pleural, pericardial)

LX. Neoplastic conditions

LX.e Breast cancer

LX. Neoplastic conditions

LX.j Pulmonary synovial sarcoma

LX. Neoplastic conditions

LX.l Chondrosarcoma

LX. Neoplastic conditions

LX.m Tumor of the heart

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (interstitial lung disease/ILD)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.i Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.p Focal/localized area of pneumonitis/fibrosis

I. Interstitial/parenchymal lung disease

I.v Relapsing or migrating pneumonitis/pneumonia (see also Id)

I. Interstitial/parenchymal lung disease

I.w Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.aa An area or areas of consolidation

XLV. Pleural and/or pericardial involvement

XLV.u The apical cap

LI. Cardiovascular involvement / toxicity

LI.b Valvular heart disease and/or dysfunction

LI. Cardiovascular involvement / toxicity

LI.c Pericardial effusion (w/wo tamponade)

LI. Cardiovascular involvement / toxicity

LI.p Coronary artery disease (subacute, chronic)

LV. Imaging

LV.i Imaging: An area or areas of involvement with a recognizable anatomic distribution

LVII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

LVII.a BAL: An excess proportion of lymphocytes

LVIII. Pathology

LVIII.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

LX. Neoplastic conditions

LX.a Lung cancer

LX. Neoplastic conditions

LX.m Tumor of the heart